Persistent Primary Hyperparathyroidism, Severe Vitamin D Deficiency, and Multiple Pathological Fractures.
Mendoza-Zubieta VictoriaMauricio Carvallo-VenegasJorge Alberto Vargas-CastillaNicolás Ducoing-SistoAlfredo Alejandro Páramo-LoveraLourdes Josefina Balcázar-HernándezJulián Malcolm Mac Gregor-GoochPublished in: Case reports in endocrinology (2016)
Persistent primary hyperparathyroidism (PHPT) refers to the sustained hypercalcemia state detected within the first six months following parathyroidectomy. When it coexists with severe vitamin D deficiency, the effects on bone can be devastating. We report the case of a 56-year-old woman who was sent to this center because of persistent hyperparathyroidism. Her disease had over 3 years of evolution with nephrolithiasis and hip fracture. Parathyroidectomy was performed in her local unit; however, she continued with hypercalcemia, bone pain, and pathological fractures. On admission, the patient was bedridden with multiple deformations by fractures in thoracic and pelvic members. Blood pressure was 100/80, heart rate was 86 per minute, and body mass index was 19 kg/m(2). Calcium was 14 mg/dL, parathormone 1648 pg/mL, phosphorus 2.3 mg/dL, creatinine 2.4 mg/dL, urea 59 mg/dL, alkaline phosphatase 1580 U/L, and vitamin D 4 ng/mL. She received parenteral treatment of hypercalcemia and replenishment of vitamin D. The second surgical exploration was radioguided by gamma probe. A retroesophageal adenoma of 4 cm was resected. Conclusion. Persistent hyperparathyroidism with severe vitamin D deficiency can cause catastrophic skeletal bone softening and fractures.
Keyphrases
- heart rate
- blood pressure
- bone mineral density
- hip fracture
- body mass index
- heart rate variability
- early onset
- soft tissue
- bone loss
- chronic pain
- spinal cord
- case report
- physical activity
- rectal cancer
- postmenopausal women
- neuropathic pain
- skeletal muscle
- quantum dots
- pain management
- drug induced
- adipose tissue
- blood glucose
- replacement therapy
- single molecule
- combination therapy
- glycemic control